Valuation: BioNTech SE

Capitalization 19.64B 23.08B 18.34B 17.2B 31.81B 2,082B 34.63B 214B 83.01B 984B 86.62B 84.79B 3,584B P/E ratio 2025 *
-24.1x
P/E ratio 2026 * -32.8x
Enterprise value 9.01B 10.59B 8.41B 7.89B 14.6B 955B 15.89B 98.03B 38.09B 451B 39.75B 38.91B 1,645B EV / Sales 2025 *
3.35x
EV / Sales 2026 * 3.54x
Free-Float
86.48%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: BioNTech SE

1 day+0.28%
Current month-6.93%
1 month-11.64%
3 months-7.97%
6 months-8.97%
Current year-15.75%
More quotes
1 week 94.52
Extreme 94.52
99.56
1 month 94
Extreme 94
106.75
Current year 81.2
Extreme 81.2
129.27
1 year 81.2
Extreme 81.2
129.27
3 years 76.53
Extreme 76.5301
188.98
5 years 76.53
Extreme 76.5301
464
10 years 12.52
Extreme 12.525
464
More quotes
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO 52 2014-08-31
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 68 2008-06-01
Director/Board Member 64 2017-12-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.28%0.00%-19.56%-43.63% 23.02B
-1.74%-4.47%+30.44%+104.87% 54.9B
+2.84%-4.78%+163.13%+957.64% 40.49B
+0.70%+4.25%+61.90%+16.75% 39.05B
+2.74%-0.78%+33.20%-36.30% 19.13B
-0.36%+2.27%+83.70%-35.66% 17.81B
+0.28%-4.36%-4.16%+358.93% 13.83B
+2.90%-2.66%+83.31%+200.87% 13.83B
+3.41%-2.54%+86.37%+753.88% 12.55B
-0.29%-9.48%+119.16% - 12.35B
Average +1.08%-1.10%+63.75%+253.04% 24.7B
Weighted average by Cap. +0.74%-1.38%+64.86%+255.97%
See all sector performances

Financials

2025 *2026 *
Net sales 2.69B 3.16B 2.51B 2.35B 4.35B 285B 4.74B 29.23B 11.36B 135B 11.85B 11.6B 490B 2.59B 3.05B 2.42B 2.27B 4.2B 275B 4.57B 28.22B 10.97B 130B 11.44B 11.2B 473B
Net income -877M -1.03B -819M -768M -1.42B -92.97B -1.55B -9.54B -3.71B -43.92B -3.87B -3.79B -160B -530M -623M -495M -464M -858M -56.15B -934M -5.76B -2.24B -26.53B -2.34B -2.29B -96.66B
Net Debt -10.63B -12.49B -9.92B -9.31B -17.21B -1,127B -18.74B -116B -44.92B -532B -46.87B -45.88B -1,939B -10.47B -12.3B -9.77B -9.17B -16.95B -1,110B -18.45B -114B -44.23B -524B -46.16B -45.18B -1,910B
More financial data * Estimated data
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
6,772
More about the company
Date Price Change Volume
25-12-11 96.00 $ +0.28% 1,185,056
25-12-10 95.74 $ -0.12% 958,274
25-12-09 95.85 $ -1.47% 1,548,700
25-12-08 97.28 $ +1.07% 1,569,953
25-12-05 96.25 $ +0.26% 1,270,288

Delayed Quote Nasdaq, December 11, 2025 at 04:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
81.68EUR
Average target price
118.09EUR
Spread / Average Target
+44.58%
Consensus

Quarterly revenue - Rate of surprise